Gladyshev
Eugene Gladyshev, Los Gatos, CA US
Pavel Gladyshev, Dublin IE
Patent application number | Description | Published |
---|---|---|
20110276770 | METHOD AND SYSTEM FOR ANALYSING MOST RECENTLY USED REGISTRY KEYS - A method is disclosed for analysing a computing device including a non-volatile storage medium in which a set of snapshots is stored. Each snapshot comprises at least one most recently used, MRU, key for an application, at least one MRU key having a plurality of elements. The method comprises comparing a first MRU key from a first snapshot for a first time and a corresponding second MRU key for a second snapshot for a second time temporally following said first time. If the second MRU key has a second element identified as less recently used than a first element of the second MRU key and the second element of the first MRU key is identified as not being less recently used than the first element of the first MRU key, the first element is labelled as having been newly modified between the first and second times. | 11-10-2011 |
Vadim Gladyshev, Lincoln, NE US
Patent application number | Description | Published |
---|---|---|
20090269807 | Compositions and Methods for the Expression of Selenoproteins in Eukaryotic Cells - Recombinant nucleic acid constructs for the efficient expression of eukaryotic selenoproteins and related methods for production of recombinant selenoproteins are provided. The nucleic acid constructs comprise novel selenocysteine insertion sequence (SECIS) elements. Certain novel SECIS elements of the invention contain non-canonical quartet sequences. Other novel SECIS elements provided by the invention are chimeric SECIS elements comprising a canonical SECIS element that contains a non-canonical quartet sequence and chimeric SECIS elements comprising a non-canonical SECIS element that contains a canonical quartet sequence. The novel SECIS elements of the invention facilitate the insertion of selenocysteine residues into recombinant polypeptides. | 10-29-2009 |
20110178072 | STEREOSPECIFICITY OF METHYLSULFINYL REDUCTION - This disclosure relates to compositions and methods of use involving compounds (e.g., drugs) containing methylsulfinyl moieties. For example, a compound may be administered in an excess of either the R- or S-epimer of the methylsulfinyl moiety based on whether the compound exhibits higher biological activity when the methylsulfinyl moiety is present in the methylsulfinyl-oxidized form or the methylsulfide-reduced form. | 07-21-2011 |
Vadim N. Gladyshev, Lincoln, NE US
Patent application number | Description | Published |
---|---|---|
20090087852 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 04-02-2009 |
20100255491 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 10-07-2010 |